aTyr Pharma, Inc. (NASDAQ:ATYR) Receives $20.20 Average Price Target from Analysts

aTyr Pharma, Inc. (NASDAQ:ATYR) has been given a consensus rating of “Buy” by the six brokerages that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $21.25.

A number of research analysts have issued reports on ATYR shares. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a research report on Wednesday, June 4th. Wall Street Zen downgraded shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Finally, Wells Fargo & Company upped their price target on shares of aTyr Pharma from $17.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, June 20th.

aTyr Pharma Stock Performance

aTyr Pharma stock opened at $4.99 on Tuesday. aTyr Pharma has a 12-month low of $1.67 and a 12-month high of $7.29. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $5.35 and its two-hundred day moving average price is $4.16. The stock has a market cap of $488.97 million, a PE ratio of -6.24 and a beta of 0.94.

aTyr Pharma (NASDAQ:ATYR) last released its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). As a group, analysts expect that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ATYR. Group One Trading LLC acquired a new position in shares of aTyr Pharma in the 4th quarter worth approximately $26,000. California State Teachers Retirement System acquired a new position in shares of aTyr Pharma in the 2nd quarter worth approximately $28,000. Y Intercept Hong Kong Ltd acquired a new position in shares of aTyr Pharma in the 1st quarter worth approximately $38,000. Raymond James Financial Inc. acquired a new position in shares of aTyr Pharma in the 4th quarter worth approximately $39,000. Finally, XTX Topco Ltd acquired a new position in shares of aTyr Pharma in the 4th quarter worth approximately $40,000. Institutional investors own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.